Rescheduling Psilocybin

Hopkins researchers recommend reclassifying psilocybin, the drug in 'magic' mushrooms, from schedule I to schedule IV

Evaluation of psilocybin safety and abuse research shows that the drug has low potential for abuse and dependence, scientists say.

Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.